<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1523</id>
    <completedYear/>
    <publishedYear>2022</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>44</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2022-06-13</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2022-03-11</thesisDateAccepted>
    <title language="eng">Contribution of relocated biology technologies and mobile health for the estimation of cardiovascular risks.</title>
    <abstract language="eng">Cardiovascular diseases (CVDs) are the first mortality causes in the world (Khan 2021) and one of the main causes of death in Belgium. It is gauged that 17.9 million lives are taken every year worldwide. They are the causes of multiple issues, such as premature death or disabilities. They are as well causing a consequent impact on socio-economic aspects.&#13;
One of the cardiovascular risks, which is one of the main thematic of this thesis is Atrial Fibrillation (AF). AF is not a new pathology, it was already described in 1827 by Robert Adams, and then in the 20th century, William Einthoven, by inventing electrocardiography, enabled the first record of it (Staerk, Sherer, Ko et al. ,year 2017). AF is a type of cardiac arrhythmia, and the most sustained one. In Belgium it is estimated that 150 000 persons are affected by it. Being an important factor in the prevention of Heart Failures (HF) and Cardiovascular risks, the management, and the screening of it are a predominant matter taking in consideration the risks brought by it. Different protocols are established in hospitals, however it is a bit more limited in general practitioner’s offices (GP practices). The introduction to digital health devices can as well be delicate, as many benefits they can offer, a few disadvantages have to be taken into account in order to include them to a proper protocol. Establishing a protocol including different factors such as relocated biology technologies and mobile health, while being external to the GP practices, can prove itself to be a challenge.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-15232</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-ND 4.0 International - Namensnennung-Keine Bearbeitungen</licence>
    <author>Anne-Victoria Roehrich</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Cardiology</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Biotechnologies</value>
    </subject>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1523/Roehrich_bachelorthesis.pdf</file>
  </doc>
</export-example>
